Posted by Michael Wonder on 18 Mar 2025
Skyclarys (omaveloxolone) approval by Health Canada ushers in a new era for Friedreich's ataxia treatment in Canada
17 March 2025 - As the only approved treatment to address disease progression, Skyclarys addresses a long standing gap in the care of Canadians living with Friedreich's ataxia.
Biogen Canada is pleased to announce that Health Canada has approved Skyclarys (omaveloxolone) for the treatment of Friedreich's ataxia in patients 16 years of age and older.
